Actively Recruiting
A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2025-09-26
25
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if spatially fractionated radiotherapy (SFRT) combined with standard systemic therapy can treat oligoprogressive non-small cell lung cancer (NSCLC) in patients who have progressed after at least one line of systemic therapy. The main question it aims to answer is: \- Can the combination of SFRT and standard systemic therapy improve progression-free survival (PFS) compared to standard systemic therapy alone? Participants will: * Undergo SFRT treatment for oligoprogressive lesions, with specific dose fractionation determined by the radiation oncologist based on clinical parameters. * Continue their standard systemic therapy, which may include chemotherapy, targeted therapy, or immunotherapy, as adjusted by their treating physician. * Have regular follow-up assessments, including imaging studies to evaluate treatment response and monitor for disease progression.
CONDITIONS
Official Title
A Study on Using SFRT With Standard Treatment for Oligoprogressive NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, any sex
- ECOG performance status score of 2 or less with expected survival over 3 months
- Confirmed non-small cell lung cancer with up to 5 progressive lesions after at least one systemic therapy
- Target lesion for radiotherapy not previously irradiated or treated over 6 months ago
- Target lesion diameter at least 4.5 cm suitable for lattice radiotherapy
- No new or enlarged brain metastases; previously treated brain metastases must be stable
- Adequate blood counts and liver and kidney function within specified limits
- Negative pregnancy test within 7 days for women of childbearing potential
You will not qualify if you...
- Other systemic diseases or severe comorbidities interfering with safety or assessment
- Active or severe autoimmune diseases including interstitial lung disease
- Uncontrolled infections or serious concurrent illnesses such as active tuberculosis, active hepatitis B or C, severe gastrointestinal diseases, or unstable heart conditions
- Mental illness or social situations limiting study compliance
- Participation in other experimental drug trials for the primary tumor
- Allergy or prior severe adverse reactions to immunotherapy drugs
- History of other active cancers within 6 months except certain treated cancers with low recurrence risk
- History of allogeneic organ transplantation or active primary immunodeficiency
- Any other condition deemed unsuitable by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
2nd Affiliated Hospital, School of Medicine
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
Research Team
T
Ting Zhang, phD.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here